Treatment of Hereditary Hemorrhagic Telangiectasia-Related Epistaxis

Nathan B Sautter; Timothy L Smith

doi:10.1016/j.otc.2016.02.010

Treatment of Hereditary Hemorrhagic Telangiectasia-Related Epistaxis

Otolaryngol Clin North Am. 2016 Jun;49(3):639-54. doi: 10.1016/j.otc.2016.02.010.

Authors

Nathan B Sautter¹, Timothy L Smith²

Affiliations

¹ Department of Otolaryngology - Head and Neck Surgery, Oregon Sinus Center, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA. Electronic address: nsautter@gmail.com.
² Department of Otolaryngology - Head and Neck Surgery, Oregon Sinus Center, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA.

PMID: 27267016
DOI: 10.1016/j.otc.2016.02.010

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with an incidence of 1:5000. Recurrent, spontaneous epistaxis is the most common presenting symptom. Severity of epistaxis varies widely, from mild, self-limited nosebleeds to severe, life-threatening nasal hemorrhage. Treatment of HHT-related epistaxis presents a challenge to the otolaryngologist due to the recurrent, persistent nature of epistaxis often requiring multiple treatments. Treatment modalities range from conservative topical therapies to more aggressive surgical treatments.

Keywords: Bevacizumab; Epistaxis; Hereditary hemorrhagic telangiectasia (HHT); Laser photocoagulation; Osler-Weber-Rendu; Septodermoplasty; Young’s procedure.

Publication types

Review

MeSH terms

Combined Modality Therapy / methods
Endoscopy* / adverse effects
Endoscopy* / methods
Epistaxis / surgery*
Hemostasis, Surgical / methods*
Hemostatic Techniques*
Hemostatics / pharmacology*
Humans
Outcome and Process Assessment, Health Care
Secondary Prevention / methods
Severity of Illness Index
Telangiectasia, Hereditary Hemorrhagic / complications*

Substances

Hemostatics